Patents by Inventor Gary J. Nabel

Gary J. Nabel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10744199
    Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 18, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
  • Publication number: 20200149069
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: January 24, 2020
    Publication date: May 14, 2020
    Applicants: The Government of the United States of America as Represented by the Secretary of the Department of, GlaxoSmithKline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Publication number: 20200085938
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 19, 2020
    Inventors: Gary J. NABEL, Wataru AKAHATA, Srinivas RAO
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Publication number: 20200054765
    Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 20, 2020
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
  • Patent number: 10369208
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: August 6, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • Publication number: 20190153041
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Application
    Filed: November 26, 2018
    Publication date: May 23, 2019
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Publication number: 20190054182
    Abstract: Provided herein are compositions comprising trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins or one or more T-cell receptors, where in a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 21, 2019
    Applicants: Sanofi, The USA, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Ling XU, Ronnie WEI, Huawei QIU, Jochen BENINGA, Jochen KRUIP, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Mark CONNORS, John R. MASCOLA, Richard A. KOUP, Jinghe HUANG, Nicole A. DORIA-ROSE, Tongqing ZHOU, Peter D. KWONG, Young Do KWON, Amarendra PEGU, Mangaiarkarasi ASOKAN
  • Publication number: 20190016786
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 17, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Patent number: 10137190
    Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 27, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Masaru Kanekiyo, Chih-Jen Wei, Patrick M. McTamney, Hadi M. Yassine, Jeffrey C. Boyington
  • Patent number: 10138277
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 27, 2018
    Assignee: The United States of America as Represented by the Secretary Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Patent number: 10035844
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 31, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Publication number: 20170320967
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 13, 2017
    Publication date: November 9, 2017
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Lan WU, Edward SEUNG, Ronnie WEI, Jochen BENINGA, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Carsten CORVEY
  • Publication number: 20170267748
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Patent number: 9701718
    Abstract: Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: July 11, 2017
    Assignees: Janssen Vaccines & Prevention B.V., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Maria Grazia Pau, Jaap Goudsmit
  • Publication number: 20170189518
    Abstract: Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
    Type: Application
    Filed: August 23, 2016
    Publication date: July 6, 2017
    Inventors: Gary J. NABEL, Masaru KANEKIYO, Chih-Jen WEI, Patrick M. MCTAMNEY, Hadi M. YASSINE, Jeffrey C. BOYINGTON
  • Patent number: 9695230
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: July 4, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Publication number: 20170073377
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 16, 2017
    Inventors: Gary J. NABEL, Srinivas RAO, Wataru AKAHATA
  • Publication number: 20170044571
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: October 31, 2016
    Publication date: February 16, 2017
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 9526777
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 27, 2016
    Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca